Anxiety symptoms were assessed using the Generalized Anxiety Disorder questionnaire (GAD-7)1, a patient-completed, validated screening measure for symptoms of anxiety. The mean GAD-7 score improved from 5.3 at the initial visit to 4.5 at the last follow-up visit in patients treated with antiepileptic medications only (P < 0.0001). N = adult epilepsy patients with at least 6 months of follow-up. Mean duration of follow-up was 37.3 months. The standard box plots reflect the median and the 25th and 75th quartiles.
In the medical group, 21.4% of patients had moderate to severe anxiety symptoms at their initial visit, as defined by GAD-7 score ≥ 10. Anxiety symptoms resolved (GAD-7 score < 5) by the last follow-up in 29.9% of this symptomatic group. In another 26% of patients, the severity of anxiety was significantly lessened (GAD-7 scores = 5–10), while the rest remained stable. However, anxiety worsened from mild to moderate/severe in 20.3% and developed de novo in 5.5% during follow-up.